The Limestone County Emergency Management Agency said early Saturday morning that it has one outdoor warning siren still out of service and awaiting parts for repairs.
The EMA warns of products being sold as dendritic cell therapies with little evidence, but high health risks, in the European ...
Discover how outsourcing regulatory submission content development improves efficiency and ensures compliance.
Mía had dystrophic epidermolysis bullosa, better known as butterfly skin due to the extreme fragility of this tissue in ...
The Morgan County Commission will pay $25,000 for an Emergency Management Agency Hazard Mitigation Plan to be completed that ...
Exogenus Therapeutics Taps Lonza to Develop a GMP-Compliant Process for Lead Exosome-Based Candidate
Lonza will leverage its expertise in exosome development and analytical services to define a GMP-compliant process for Exo-101 production.
MaaT Pharma (EURONEXT: MAAT ? the "Company"), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for ...
Post-authorisation safety studies (PASS) are often seen simply as a regulatory necessity, a checkbox that ensures ongoing ...
13d
Pharmaceutical Technology on MSNEU set to approve AstraZeneca’s Imfinzi-chemo combo for NSCLCAstraZeneca's Imfinzi (durvalumab) plus chemotherapy combo has received the European Medicines Agency’s (EMA) Committee for ...
EMA committee recommends approval of AbbVie’s upadacitinib to treat adults with giant cell arteritis
AbbVie announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of upadacitinib (Rinvoq; 15 mg, once ...
FYB202/Otulfi ® (ustekinumab-aauz), a biosimilar to Stelara®, launched in the United States and the European Union FYB202/Otulfi ® is now commercially available in both subcutaneous and intravenous ...
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended three novel medicines for approval at its February 2025 meeting. The European Commission is expected to announce a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results